PEBBLES
ACTRN12617001380381
Commercial sector/Industry, Primus Pharmaceuticals
A/Prof Adrian Lowe
The primary objective of this study is to demonstrate that twice daily application of a ceramide dominant emollient reduces the risk of eczema and food allergy, when compared to standard skin management. Secondary objectives are to determine if twice daily application of a ceramide dominant emollient reduces the risk of infants developing allergic sensitisation (as measured by skin prick test); to determine if twice daily application of a ceramide dominant emollient improves infant skin barrier .... Read more
Infants will be eligible for this study if their mother, father, or an older sibling has a self-reported history of at least one of the following conditions: asthma, eczema/atopic dermatitis, hay fever/ allergic rhinitis or food allergy. All families who participated in the original PEBBLES trial will be invited to participate in the 4-year follow-up.
Infants with any of the following will be excluded: A parent who has a known hypersensitivity to any of the ingredients of EpiCeram™ will be excluded, as it would be difficult for these parents to apply EpiCeram™ to their infant, and there is likely to be an increased risk of the infant reacting to the cream. Multiple births (twins, triplets etc.) will be excluded, due to the difficulty in randomising individual twins and because of the clustering effect of multiple children from the same family .... Read more
Yes
Sample Size 425
Min. age No limit
Max. age 3 Weeks
Sex Both males and females
Condition category Asthma , Behavioural problems , Eczema/Atopic Dermatitis , Emotional Problems , Food Allergy
Condition code Skin
Intervention code Prevention , Treatment: Drugs
The PEBBLES trial involved the twice-daily application of a ceramide-dominant emollient (EpiCeram™) during early infancy. EpiCeram™ contains a formulation that includes Capric Acid, Cholesterol, Citric Acid, Conjugated Linoleic Acid, Dimethicone, Disodium EDTA, E. Cerifera (Candelilla) Wax, Food Starch Modified Corn Syrup Solids, Glycerin, Glyceryl Stearate, Hydroxypropyl Bispalmitamide MEA (Ceramide), Palmitic Acid, PEG-100 Stearate, Petrolatum, Phenoxyethanol, Potassium Hydroxide, Purified Wat .... Read more
Control group Active
The study staff will not provide any directions to parents in the control arm on how to manage their child's skin. No attempt will be made to alter or influence parents treatment of their child's skin in this arm of the study. This is defined as standard skin care. Duration of care is 6 months.
Outcome: Confirmed diagnosis of food allergy at 12 months (52 weeks). This diagnosis is derived from a combination of allergic sensitisation, reaction history and food challenge. A skin prick test to six common allergens will be performed (egg white, cows’ milk, peanut, dust mite, cat dander, and rye grass) along with a negative (saline) and a positive (histamine) control. Participants that are sensitised to certain foods (>=1mm wheal) during the skin prick testing will be give .... Read more
Outcome: Presence of eczema as assessed using i) the UK working party criteria for eczema and/or ii) blinded investigator observed eczema. Timepoint: 12 months of age.
yes
Intervention group, outcome data, and potential predictors of outcome.
from 1/10/2021 onwards (no end date)
Academic researchers
Grouped analyses or individual participant meta-analyses.
To assist secondary data users in understanding the real-world impact of health and medical research data sharing, the Australian Research Data Commons (ARDC) has created an online guide that outlines a theoretical framework for four key data reuse scenarios. This practical guide was extracted from research papers, and consultation with stakeholders and the research community.
With Health Data Australia, researchers can explore descriptions of data from our publishing partners, identify relevant datasets, and request access. These requests will then be forwarded to the data owner for review.
To start requesting data, simply login with your AAF account.